That is what we used to say in the Navy.

my hope is that a lot of folks, including people in this room... will answer that call as well.

We cannot forget them. I am not going to, and I do not think you want us to do that.

I think finding a way to get better competition and less regulation, I think, would free up and bring more carriers into the market.

Insurance does not work really well when you are only insuring the people who really need it.

the Affordable Care Act is working in their States, lowering the uninsured rate and improving their insurance marketplaces.

My Republican colleagues, several of them, have recently introduced legislation to roll back the individual mandate.

Medicaid expansion has been critical to lowering the cost of private insurance and improving the health of their residents.

We had the longest markup in history on the Finance Committee.

Mr. Speaker, I was unable to vote on rollcall 505, 506, and 507. I would have voted ``no'' on rollcall 505 and 506, and ``aye'' on rollcall 507 had I been there. ____________________

Mr. Speaker, I was unavoidably detained. Had I been present, I would have voted ``nay'' on rollcall No. 506. ____________________

In this great country of ours, we had folks who knew that if they got sick, that might mean personal bankruptcy for them.

You have talked a great deal about how we have to keep robust competition.

Do you think it would be good to have public hearings before a major merger of the magnitude that we are seeing in Ohio, which will limit competition?

So, maybe, I will open it to the panelists and maybe Mr. Kreidler will mention--what should we be doing? And then, the others--what should we be doing to reign in these outrageous price increases from drug companies when there is not even…

I have never seen a perfect bill. I do not think one exists and never will exist, so you have to go back and refine it and try to find those changes.

I am particularly concerned--and I am sure my colleagues have received all sorts of correspondence on what is happening with drug manufacturers--the recent EpiPen situation, where you have a drug that really has not changed much in years…

We have to figure out how to deal with some of these very complex issues and do it in a collaborative way.